BioMarin Pharmaceutical (BMRN) Stock Price, Quote, News & History

Comments

BioMarin Pharmaceutical Inc (BMRN) Stock Price, Quote, News & History

BMRNNASDAQ

Trade with Public

$54.13

-0.90-1.64%

At close: Mar 20, 5:00 PM EST

$54.08

-0.05-0.09%

After Hours: 4:08 PM EST

OverviewNews Earnings Options Guidance Analyst Ratings Insider Trades Short Interest Government Trades Stock Report

Key Statistics

Open

$54.86

Close

$54.13

Volume / Avg.

4.35M / 2.49M

Day Range

$53.76 - $55.71

52 Wk Range

50.76 - 73.18

Market Cap

$10.39B

P/E Ratio

30.57

Dividend Yield

-

Exchange

NASDAQ

RSI

29

Short Interest

5.51%

Days to Cover

3.53

Recent BioMarin Pharmaceutical Inc News

BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz

BridgeBio's rare-disease pipeline draws investor attention as new therapies near regulatory filings and potential commercial launches.

Vandana Singh

BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients

The FDA approved BioMarin's supplemental BLA for Palynziq, a treatment for PKU in adolescents 12 and older.

Vandana Singh

These Analysts Revise Their Forecasts On BioMarin Pharmaceutical After Q4 Results

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

827.99M

Investing Cash Flow (TTM)

-414.24M

Financing Cash Flow (TTM)

-42.39M

Free Cash Flow (TTM)

717.02M

Capital Expenditure (TTM)

-110.98M

Net Change in Cash (TTM)

371.36M

Analyst Trends and Forecast

1

2

Dec 25

1

Jan

6

1

Feb

2

1

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.7

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$9.63B

PE Ratio (TTM)

30.57

PE Ratio (FWD)

10.88

PEG Ratio (TTM)

0.64

PS Ratio (TTM)

3.37

PB Ratio (TTM)

1.74

Earnings Yield % (TTM)

3.27%

Earnings Yield % (FWD)

9.19%

EV / EBITDA (TTM)

16.80

Price / EBITDA (TTM)

18.96

Price / Free Cash Flow (TTM)

15.15

Book Value / Share

$31.65

Company Debt

Total Debt

$597.18M

LT Debt

$597.18M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

$0

Total Cash

$1.31B

Debt to Equity

0.10

Issuance of Debt (TTM)

$0

Repayment of Debt (TTM)

$0

Key Statistics

Open

$54.86

Close

$54.13

Volume / Avg.

4.35M / 2.49M

Day Range

$53.76 - $55.71

52 Wk Range

50.76 - 73.18

Market Cap

$10.39B

P/E Ratio

30.57

Dividend Yield

-

Exchange

NASDAQ

RSI

29

Short Interest

5.51%

Days to Cover

3.53

About

Sector

Health Care

Industry

Biotechnology

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex ...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy BioMarin Pharmaceutical (BMRN) stock?

A

You can purchase shares of BioMarin Pharmaceutical (NASDAQ:BMRN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are BioMarin Pharmaceutical (BMRN) competitors?

A

Other companies in BioMarin Pharmaceutical’s space includes: Exact Sciences Corp (NASDAQ:EXAS), Neurocrine Biosciences Inc (NASDAQ:NBIX), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Roivant Sciences Ltd (NASDAQ:ROIV) and Protagonist Therapeutics Inc (NASDAQ:PTGX).

Q

What is the forecast, or price target, for BioMarin Pharmaceutical (BMRN) stock?

A

BioMarin Pharmaceutical has a consensus price target of $90.25.

Q

What is the current price for BioMarin Pharmaceutical (BMRN)?

A

The stock price for BioMarin Pharmaceutical (NASDAQ: BMRN) is $54.08 last updated March 20, 2026 at 4:08 PM EDT.

Q

Does BioMarin Pharmaceutical (BMRN) pay a dividend?

A

There are no upcoming dividends for BioMarin Pharmaceutical.

Q

When is BioMarin Pharmaceutical (NASDAQ:BMRN) reporting earnings?

A

BioMarin Pharmaceutical does not have any upcoming earnings scheduled.

Q

Is BioMarin Pharmaceutical (BMRN) going to split?

A

There is no upcoming split for BioMarin Pharmaceutical.

Q

What sector and industry does BioMarin Pharmaceutical (BMRN) operate in?

A

BioMarin Pharmaceutical is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Neurocrine Biosciences Inc

NASDAQ:NBIX

$127.68

%

Ionis Pharmaceuticals Inc

Protagonist Therapeutics Inc

Arrowhead Pharmaceuticals Inc

NASDAQ:ARWR

$57.18

1.51%

Madrigal Pharmaceuticals Inc

NASDAQ:MDGL

$441.16

%

Key Statistics

Open

$54.86

Close

$54.13

Volume / Avg.

4.35M / 2.49M

Day Range

$53.76 - $55.71

52 Wk Range

50.76 - 73.18

Market Cap

$10.39B

P/E Ratio

30.57

Dividend Yield

-

Exchange

NASDAQ

RSI

29

Short Interest

5.51%

Days to Cover

3.53

Recent BioMarin Pharmaceutical Inc News

BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz

BridgeBio's rare-disease pipeline draws investor attention as new therapies near regulatory filings and potential commercial launches.

Vandana Singh

BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients

The FDA approved BioMarin's supplemental BLA for Palynziq, a treatment for PKU in adolescents 12 and older.

Vandana Singh

These Analysts Revise Their Forecasts On BioMarin Pharmaceutical After Q4 Results

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

827.99M

Investing Cash Flow (TTM)

-414.24M

Financing Cash Flow (TTM)

-42.39M

Free Cash Flow (TTM)

717.02M

Capital Expenditure (TTM)

-110.98M

Net Change in Cash (TTM)

371.36M

Analyst Trends and Forecast

1

2

Dec 25

1

Jan

6

1

Feb

2

1

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.7

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$9.63B

PE Ratio (TTM)

30.57

PE Ratio (FWD)

10.88

PEG Ratio (TTM)

0.64

PS Ratio (TTM)

3.37

PB Ratio (TTM)

1.74

Earnings Yield % (TTM)

3.27%

Earnings Yield % (FWD)

9.19%

EV / EBITDA (TTM)

16.80

Price / EBITDA (TTM)

18.96

Price / Free Cash Flow (TTM)

15.15

Book Value / Share

$31.65

Company Debt

Total Debt

$597.18M

LT Debt

$597.18M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

$0

Total Cash

$1.31B

Debt to Equity

0.10

Issuance of Debt (TTM)

$0

Repayment of Debt (TTM)

$0

Key Statistics

Open

$54.86

Close

$54.13

Volume / Avg.

4.35M / 2.49M

Day Range

$53.76 - $55.71

52 Wk Range

50.76 - 73.18

Market Cap

$10.39B

P/E Ratio

30.57

Dividend Yield

-

Exchange

NASDAQ

RSI

29

Short Interest

5.51%

Days to Cover

3.53

About

Sector

Health Care

Industry

Biotechnology

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex ...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry